BRVE — Braveheart Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2131524 ·
Last close
$18.78
Market Cap
$1.69B
52W High
$32.00
52W Low
$16.70
ADV30
408,433
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -30,149,000 | -26,495,000 | 514,450,000 | 121,291,000 | 16,848,000 |
| Jun 2026 | 0 | — | -15,882,000 | -14,988,000 | 126,956,000 | 122,831,000 | 222,862,000 |
| Mar 2026 | 0 | — | -15,049,000 | -14,280,000 | 81,878,000 | 80,576,000 | 160,270,000 |
| Dec 2025 | 0 | — | -6,982,000 | -6,454,000 | 89,350,000 | 89,161,000 | 155,222,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,783,000
Investing CF
$-386,313,000
Financing CF
$487,855,000
CapEx
$-3,871,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.52
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-122,402,000
Inventory
—
Receivables
—
ST Investments
$227,981,000
EBIT TTM
$-68,062,000
Pretax Income TTM
$-62,217,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 1y)
Revenues vs Net Income (last 1y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -4,505,000 | -66,052,000 | 89,350,000 | 155,222,000 | -65,872,000 | -2,014,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$126,956,000
Forward EPS
$-1.99
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SUPN | Supernus, Inc. | $1.69B | $29.04 | — |
| SDGR | Schrodinger, Inc. | $1.68B | $25.66 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.70B | $16.70 | — |
| STOK | Stoke Therapeutics, Inc. | $1.73B | $26.41 | — |
| ZYME | Zymeworks Inc. | $1.78B | $25.84 | — |
News headlines (Yahoo Finance, 1h cache)
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-10 21:03 · Yahoo
Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
2026-11-09 12:30 · Yahoo
Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial
2026-11-07 01:14 · Yahoo
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Se
2026-11-06 20:15 · Yahoo
Where Does Braveheart Bio (BRVE) Value Sit After AHA Data?
2026-11-05 06:14 · Yahoo
Braveheart Bio (BRVE), Why Is Attention Building Around It?
2026-11-04 10:20 · Yahoo
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
2026-10-30 11:30 · Yahoo
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
2026-10-30 11:30 · Yahoo
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
2026-09-16 20:30 · Yahoo
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-09-08 20:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.